fulvestrant has been researched along with everolimus in 38 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.63) | 29.6817 |
| 2010's | 31 (81.58) | 24.3611 |
| 2020's | 6 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Beeram, M; DeGraffenried, LA; Middleton, A; Russell, D; Tan, QT; Tekmal, RR | 1 |
| Crowder, RJ; Ellis, MJ; Gao, F; Guintoli, T; Lin, L; Ma, CX; Phommaly, C; Sanchez, CG | 1 |
| Mehta, A; Tripathy, D | 1 |
| Bachelot, T; Duffy, S; Fleetwood, K; Glanville, J; Jerusalem, G; McCool, R; Varley, D; Zhang, J | 1 |
| Black, EP; Elledge, R; Kadamyan-Melkumian, V; Massarweh, S; Romond, E; Shelton, B; Stevens, M; Van Meter, E | 1 |
| Barrow, D; Dutkowski, CM; Gee, JM; Guichard, SM; Hutcheson, IR; Jordan, NJ; Mottram, HJ; Nicholson, RI | 1 |
| Al-Qaisi, A; Awasthi, M; Chen, A; Chen, L; Kadamyan-Melkumyan, V; Massarweh, S; Romond, E | 1 |
| Bachelot, T; Barrios, C; de Boer, R; Di Leo, A; Janni, W; Jerusalem, G; Neven, P | 1 |
| Anderson, L; Chen, D; Conklin, D; Dering, J; Desai, AJ; Finn, RS; Hurvitz, SA; Kalous, O; Kolarova, T; Linnartz, R; O'Brien, NA; Slamon, DJ | 1 |
| Bachelot, T; Bally, O; Heudel, P; Kassem, L; Tredan, O; Vanacker, H | 1 |
| Hao, Y; Koo, V; Li, N; Lin, PL; Ohashi, E; Rogerio, J; Wu, EQ; Xie, J | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Kimura-Tsuchiya, R; Saji, S; Sasaki, E | 1 |
| Batson, S; Jones, N; Livings, C; Telford, C | 1 |
| Bao, H; Barry, E; Bihani, T; Bradford, J; Collins, M; D'Cruz, CM; Fawell, S; Goeppert, AU; Hearne, K; Hollingsworth, R; Hurt, E; Jalla, S; Ladd, B; Lai, Z; Mazzola, AM; Mohseni, M; Reimer, C; Renshaw, JG; Weir, HM; Zinda, M | 1 |
| Katzenellenbogen, BS; Piccart, M; Tryfonidis, K; Zardavas, D | 1 |
| Niraula, S; Ocana, A | 1 |
| Caramia, F; Joshi, S; Loi, S; Moodie, K; Savas, P; Van Geelen, C; Wein, L | 1 |
| Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D | 1 |
| Chen, S; Huang, TT; Liu, CY; Petrossian, K; Tseng, LM; Wu, CY | 1 |
| Abenhardt, W; Beckmann, MW; Belleville, E; Brucker, SY; Ettl, J; Fasching, PA; Fehm, TN; Fersis, N; Geberth, M; Häberle, L; Hadji, P; Hartkopf, AD; Hielscher, C; Huober, J; Janni, W; Kolberg, HC; Kurbacher, C; Lüftner, D; Lux, MP; Müller, V; Nabieva, N; Overkamp, F; Schneeweiss, A; Schwitulla, J; Taran, FA; Tesch, H; Thomssen, C; Untch, M; Volz, B; Wallwiener, D; Wallwiener, M; Wimberger, P; Wuerstlein, R | 1 |
| Augereau, P; Campion, L; Campone, M; Caroline, F; du Rusquec, P; Dumas, L; Frenel, JS; Gourmelon, C; Palpacuer, C; Patsouris, A; Robert, M | 1 |
| Brufsky, A; Burnette, B; Cheema, P; Goldstein, LJ; Haley, B; Klein, P; Kornblum, N; Makower, DF; Manola, J; Miller, KD; Ramaswamy, B; Soori, GS; Sparano, JA; Stella, PJ; Telli, M; Truica, CI; Wassenaar, TR; Wolff, AC; Zhao, F | 1 |
| Chaiyakunapruk, N; Imanaka, Y; Kunisawa, S; Lertjanyakun, V | 1 |
| Avogadri-Connors, F; Cutler, RE; Dowsett, M; Guest, SK; Johnston, SR; Lalani, AS; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Rani, A; Ribas, R; Schuster, E; Simigdala, N; Thornhill, A | 1 |
| Huang, HW; Huang, LS; Li, XY; Lin, JZ; Wang, HB; Xu, QN | 1 |
| Chen, Z; Gong, C; Hu, S; Hu, X; Li, Y; Wang, B; Wang, L; Xie, Y; Yuan, P; Zhang, J; Zhang, Y; Zhao, Y | 1 |
| Guan, X; Li, C; Li, L; Liu, B; Ma, F; Qian, H; Xu, B; Yi, Z | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Chen, PH; Ho, CL; Huang, TC; Kang, YN; Lee, CH; Lin, C; Wu, YY | 1 |
| Guan, X; Li, C; Li, H; Li, L; Liu, B; Ma, F; Qian, H; Rong, G; Sun, X; Wang, W; Xu, B; Yi, Z; Zhai, J | 1 |
| Albert, R; Alcon, C; Gómez Tejeda Zañudo, J; Letai, A; Montero, J; Samitier, J; Scaltriti, M; Wagle, N | 1 |
| Balcueva, E; Barlow, WE; Conlin, AK; Dy, PA; Gralow, JR; Hayes, DF; Hicks, JB; Hortobagyi, GN; Kuhn, P; Lew, DL; Moore, HCF; Pusztai, L; Schott, AF; Somlo, G; Tripathy, D; Welter, L; Yeon, CH | 1 |
| Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Acar, Ö; Akagündüz, B; Aksoy, S; Alkan, A; Almuradova, E; Altınbaş, M; Artaç, M; Aslan, F; Avşar, E; Aydıner, A; Bayoğlu, İV; Bayram, E; Baytemür, NK; Celayir, ÖM; Çelebi, A; Çetin, B; Çiçin, İ; Dede, İ; Demir, H; Demir, N; Demirci, A; Demirel, BÇ; Doğan, M; Ebinç, S; Er, Ö; Erdem, D; Erdoğan, AP; Eren, T; Ergün, Y; Ertürk, İ; Erul, E; Geredeli, Ç; Gökmen, E; Gökmen, İ; Göksu, SS; Gülbağcı, BB; Gümüş, M; Hacıbekiroğlu, İ; İmamoğlu, Gİ; Işık, D; Kahraman, S; Kalender, ME; Kalkan, Z; Kanıtez, M; Karaboyun, K; Karacin, C; Karadağ, İ; Karadurmuş, N; Karakaya, S; Kayıkçıoğlu, E; Keskinkılıç, M; Korkmaz, T; Kut, E; Kuzu, ÖF; Menekşe, S; Mocan, EE; Nayır, E; Oksuzoglu, B; Oktay, E; Öktem, İN; Okutur, K; Oyman, A; Özdemir, Ö; Öztosun, B; Paksoy, N; Paydaş, S; Şahin, E; Şakalar, T; Sakin, A; Salim, DK; Selçukbiricik, F; Selvi, O; Şendur, MAN; Seyyar, M; Sönmez, Ö; Tanrıverdi, Ö; Teker, F; Türker, S; Uğraklı, M; Uluç, BO; Ünal, OÜ; Yaren, A; Yavuzşen, T; Yıldırım, N; Yılmaz, F; Yılmaz, H | 1 |
13 review(s) available for fulvestrant and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Estradiol; Everolimus; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2014 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Nitriles; Patient Selection; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Failure; Treatment Outcome; Triazoles | 2015 |
[Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Everolimus; Female; Fulvestrant; Histone Demethylases; Humans; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Endocrine treatment in breast cancer: Cure, resistance and beyond.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Pyridines; Receptors, Estrogen; Tamoxifen | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Treatment for the endocrine resistant breast cancer: Current options and future perspectives.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Morpholines; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction | 2017 |
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Topics: Aminopyridines; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; ErbB Receptors; Everolimus; Female; Fulvestrant; Humans; Network Meta-Analysis; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; TOR Serine-Threonine Kinases | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Fulvestrant; Humans; Neoplasm Grading; Network Meta-Analysis; Piperazines; Postmenopause; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2020 |
4 trial(s) available for fulvestrant and everolimus
| Article | Year |
|---|---|
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Local; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Treatment Failure | 2014 |
Everolimus-induced hematologic changes in patients with metastatic breast cancer.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Erythrocyte Count; Erythrocyte Indices; Estradiol; Everolimus; Female; Fulvestrant; Hematologic Diseases; Humans; Leukocyte Count; Leukopenia; Neoplasm Metastasis; Sirolimus; Thrombocytopenia | 2015 |
Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Drug Synergism; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Survival Rate; Treatment Outcome | 2018 |
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor-positive Breast Cancer, SWOG S1222.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
21 other study(ies) available for fulvestrant and everolimus
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Flow Cytometry; Fulvestrant; Humans; Letrozole; Nitriles; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2007 |
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Estradiol; Estrogens; Everolimus; Female; Fulvestrant; Humans; Imidazoles; Morpholines; Mutation; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Quinolines; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2011 |
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Antagonists; Estrogen Receptor Antagonists; Everolimus; Female; Fulvestrant; Humans; Immunosuppressive Agents; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Morpholines; Multiprotein Complexes; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases | 2014 |
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.
Topics: Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Molecular Targeted Therapy; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Proportional Hazards Models; Treatment Outcome | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold?
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Pathology, Molecular; Piperazines; Precision Medicine; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; TOR Serine-Threonine Kinases; Trastuzumab | 2016 |
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; MCF-7 Cells; Mice; Mutation; Piperazines; Pyridines; Receptors, Estrogen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Everolimus Boosts Endocrine Therapy for Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Synergism; Estradiol; Everolimus; Female; Fulvestrant; Humans; Postmenopause; Survival Analysis; Treatment Outcome | 2017 |
FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gene Amplification; Goserelin; Humans; Piperazines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases | 2017 |
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Germany; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen | 2018 |
Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy-Induced Febrile Neutropenia; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Piperazines; Progression-Free Survival; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Thrombocytopenia | 2018 |
Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Everolimus; Female; Fulvestrant; Health Care Costs; Humans; Japan; Markov Chains; Middle Aged; Models, Economic; Postmenopause; Quality-Adjusted Life Years; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Toremifene | 2018 |
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Epidermal Growth Factor; Estradiol; Estrogen Receptor alpha; Estrogens; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Neoplasms, Hormone-Dependent; Quinolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tamoxifen | 2018 |
Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Breast Neoplasms; Capecitabine; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Receptor, ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2019 |
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Everolimus; Female; Fulvestrant; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Patient Selection; Precision Medicine; Receptors, Steroid; Retrospective Studies; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome | 2019 |
Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; China; Circulating Tumor DNA; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Progression-Free Survival; Retrospective Studies; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Toremifene | 2020 |
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Protein Isoforms; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Signal Transduction; Sulfonamides; Thiazoles; Thiophenes | 2021 |
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Toremifene | 2022 |
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Everolimus; Female; Fulvestrant; Humans; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2023 |